OncoMatch/Clinical Trials/NCT06548672
A Study to Assess the Safety, Pharmacokinetics, and Antitumor Activity of BC3195 in Patients With Advanced or Metastatic Cancer
Is NCT06548672 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies BC3195 for advanced cancer.
Treatment: BC3195 — This is a phase Ia/Ib, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of BC3195 in subjects with locally advanced or metastatic solid tumors in whom standard treatment has failed (either due to disease progression or intolerance). This study will consist of two parts: Dose escalation (Part 1) and dose expansion (Part 2). Each part will include a screening period, a treatment period, and follow-up period.
Check if I qualifyExtracted eligibility criteria
Cancer type
Tumor Agnostic
Biomarker criteria
Required: CDH3 expression
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: any available therapy associated with a reasonable likelihood to confer clinical benefit
who have not benefitted from or are intolerant of available therapy(ies) associated with a reasonable likelihood to confer clinical benefit
Cannot have received: systemic anticancer treatment (including investigational agents)
Exception: within 5 half-lives or 4 weeks before the first dose (whichever is shorter)
Prior systemic anticancer treatment, including investigational agents, within 5 half-lives or 4 weeks before the first dose (whichever is shorter)
Cannot have received: radiation therapy
Exception: within 2 weeks prior to the start of study treatment or with a history of radiation pneumonitis
Patients who have received radiation therapy within 2 weeks prior to the start of study treatment or with a history of radiation pneumonitis
Cannot have received: allogeneic tissue/solid organ transplantation
Previously received allogeneic tissue/solid organ transplantation
Lab requirements
Blood counts
adequate organ function
Kidney function
adequate organ function
Liver function
adequate organ function
Subjects with adequate organ function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Case Western Reserve University · Cleveland, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify